Viral Vaccine Cell Culture Media Market Distribution by Type of Cell Culture (Adherent and Suspension), Type of Media (Animal Component Free, Protein Free and Serum Free), Scale of Operation (Clinical Operations and Commercial Operations), Type of End-User (Industry Players and Non-Industry Players), and Key Geographical Regions (North America, Europe, Asia-Pacific, and Rest of the World): Industry Trends and Global Forecasts, 2022-2035
The viral vaccine cell culture market is expected to reach USD 1.6 billion in 2022 anticipated to grow at a CAGR of 5.8% during the forecast period 2022-2035.
In recent years, there has been a significant upsurge in the acceptance and demand for advanced vaccines aimed at combating various diseases. This trend has notably intensified with the emergence of COVID-19, propelling a global drive for viral vaccines. An estimated 4.5 billion individuals globally have received at least one dose of a COVID-19 vaccine, constituting roughly 60% of the world's populace. Nevertheless, with the continuous growth of the global population, the requirement for vaccines is poised to endure in the foreseeable future. Projections indicate that by 2025, the worldwide vaccines market could attain a valuation of around USD 100 billion.
The manufacture of vaccines involves intricate processes and stringent regulations, particularly when producing viral components or complete viruses. Ensuring the absence of contamination and sustaining high efficacy in vaccine cultures holds paramount importance. To tackle these challenges, pharmaceutical and biotech firms are increasingly embracing viral vaccine cell culture mediums. The unprecedented surge in demand stemming from the COVID-19 pandemic has emphasized the critical role of these mediums in efficiently generating substantial quantities of vaccines. Companies operating in the viral vaccine cell culture media market are now concentrating on serum-free and animal component-free mediums due to their diverse advantages, notably lower contamination rates.
The escalating demand for viral vaccines is fostering a corresponding opportunity for growth in the viral vaccine cell culture media market. This market is poised to witness steady expansion in the projected period, driven by the growing necessity for efficient and top-notch vaccine manufacturing processes.
Report Coverage
In recent years, there has been a significant upsurge in the acceptance and demand for advanced vaccines aimed at combating various diseases. This trend has notably intensified with the emergence of COVID-19, propelling a global drive for viral vaccines. An estimated 4.5 billion individuals globally have received at least one dose of a COVID-19 vaccine, constituting roughly 60% of the world's populace. Nevertheless, with the continuous growth of the global population, the requirement for vaccines is poised to endure in the foreseeable future. Projections indicate that by 2025, the worldwide vaccines market could attain a valuation of around USD 100 billion.
The manufacture of vaccines involves intricate processes and stringent regulations, particularly when producing viral components or complete viruses. Ensuring the absence of contamination and sustaining high efficacy in vaccine cultures holds paramount importance. To tackle these challenges, pharmaceutical and biotech firms are increasingly embracing viral vaccine cell culture mediums. The unprecedented surge in demand stemming from the COVID-19 pandemic has emphasized the critical role of these mediums in efficiently generating substantial quantities of vaccines. Companies operating in the viral vaccine cell culture media market are now concentrating on serum-free and animal component-free mediums due to their diverse advantages, notably lower contamination rates.
The escalating demand for viral vaccines is fostering a corresponding opportunity for growth in the viral vaccine cell culture media market. This market is poised to witness steady expansion in the projected period, driven by the growing necessity for efficient and top-notch vaccine manufacturing processes.
Report Coverage
- Executive summary describing overview of the current viral vaccine cell culture media market and its expected evolution in the mid to long term.
- Detailed introduction on vaccine components, historical vaccine evolution, types of viral vaccines, cell culture types, media advantages, and limitations.
- Detailed overview of 80+ viral vaccine cell culture media developers, including establishment, size, location, and market assessment based on various parameters.
- Elaborate profiles of prominent developers with information on establishment, employees, location, executives, products, finances, recent developments, and future outlook.
- Analysis of recent industry partnerships, collaborations, and expansions in viral vaccine cell culture media between 2015-2021.
- In-depth analysis of over 130 vaccine developers and 50 contract manufacturers for potential collaboration with cell culture media providers based on various parameters.
- Evaluation of viral vaccine cell culture media competitiveness considering supplier expertise and product specifications.
- Detailed analysis of leading industry players' brand perception across viral vaccine cell culture media.
- In-depth overview of industry evolution through R&D, analyzing 2800+ patents filed/granted between 2015-2021.
- Informed estimate of annual demand for viral vaccine cell culture media across key geographical regions.
- Forecast analysis of market evolution from 2022-2035, considering cell culture types, media types, scale of operation, end-users, and key regions, with conservative, base, and optimistic scenarios.
- Recapitulation of key takeaways and independent opinions on the research and analysis from preceding chapters.
- Creative Biolabs
- Jianshun Biosciences
- Thermo Fisher Scientific
- Merck
- Sartorius
- Xell
- ATZ labs
- OPM Biosciences
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
2.1. Chapter Overview
3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Viral Vaccine
3.2.1. Vaccine Components
3.2.2. Historical Evolution
3.2.3. Viral Vaccine Development
3.3. Type of Viral Vaccine
3.3.1. Whole Virus
3.3.2. Protein Subunit
3.3.3. Nucleic Acid
3.3.4 Viral Vector
3.4. Type of Cell Culture
3.5. Type of Cell Culture Media
3.6. Advantages of Cell Culture Media
3.7. Limitations Associated with Cell Culture Media
3.8. Conclusion
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Viral Vaccine Cell Culture Media: Overall Market Landscape
4.2.1. Analysis by Type of Vaccine
4.2.2. Analysis by Type of Cell Culture
4.2.3. Analysis by Type of Cell Culture Media
4.2.4. Analysis by Type of Cell Culture and Media
4.2.5. Analysis by Type of Cell Line
4.2.6. Analysis by Type of Cell Culture Media and Type of Cell Line
4.2.7. Analysis by Media Formulation
4.2.8. Analysis by Application Area
4.3. Viral Vaccine Cell Culture Media Developers: Market Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Analysis by Number of Products
5. COMPANY PROFILES
5.1. Chapter Overview
5.2. Players based in North America
5.2.1. Creative Biolabs
5.2.1.1. Company Overview
5.2.1.2. Financial Information
5.2.1.3. Product Portfolio
5.2.1.4. Future Outlook
5.2.2. Jianshun Biosciences
5.2.2.1. Company Overview
5.2.2.2. Financial Information
5.2.2.3. Product Portfolio
5.2.2.4. Future Outlook
5.2.3. Thermo Fisher Scientific
5.2.3.1. Company Overview
5.2.3.2. Financial Information
5.2.3.3. Product Portfolio
5.2.3.4. Future Outlook
5.3. Players based in Europe
5.3.1. Merck
5.3.1.1. Company Overview
5.3.1.2. Financial Information
5.3.1.3. Product Portfolio
5.3.1.4. Future Outlook
5.3.2. Sartorius
5.3.2.1. Company Overview
5.3.2.2. Financial Information
5.3.2.3. Product Portfolio
5.3.2.4. Future Outlook
5.3.3. Xell
5.3.3.1. Company Overview
5.3.3.2. Financial Information
5.3.3.3. Product Portfolio
5.3.3.4. Future Outlook
5.4. Players based in Asia-Pacific
5.4.1. ATZ labs
5.4.1.1. Company Overview
5.4.1.2. Financial Information
5.4.1.3. Product Portfolio
5.4.1.4. Future Outlook
5.4.2. OPM Biosciences
5.4.2.1. Company Overview
5.4.2.2. Financial Information
5.4.2.3. Product Portfolio
5.4.2.4. Future Outlook
6. RECENT DEVELOPMENTS AND INITIATIVES
6.1. Chapter Overview
6.2. Partnership Models
6.3. Viral Vaccine Cell Culture Media: Recent Partnerships and Collaborations
6.3.1. Analysis by Year of Partnership
6.3.2. Analysis by Type of Partnership
6.3.2.1. Analysis by Year and Type of Partnership
6.3.2.2. Analysis by Type of Partnership and Company Size
6.3.3. Most Active Players: Analysis by Number of Partnerships
6.3.4. Regional Analysis
6.3.4.1. Intercontinental and Intracontinental Agreements
6.3.5. Cumulative Year-wise Trend of Merger / Acquisition
6.3.6. Analysis by Type of Acquisition
6.3.7. Analysis by Key Value Drivers
6.3.8. Analysis by Year of Acquisition and Key Value Drivers
6.4. Viral Vaccine Cell Culture Media: Recent Expansions
7. LIKELY PARTNER ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Potential Strategic Partners for Viral Vaccine Cell Culture Media Developers
7.3.1. Likely Partner Opportunities in Preventive Vaccine Developers
7.3.2. Likely Partner Opportunities in Therapeutic Vaccine Developers
7.3.3. Likely Partner Opportunities in Vaccine Contract Manufacturers
8. PRODUCT COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Methodology
8.3. Assumptions / Key Parameters
8.4. Product Competitiveness: Adherent Cell Culture Media
8.5. Product Competitiveness: Suspension Cell Culture Media
9. BRAND POSITIONING
9.1. Chapter Overview
9.2. Key Parameters and Methodology
9.3. Brand Positioning Matrix: Cytiva
9.4. Brand Positioning Matrix: FUJIFILM Wako Chemicals
9.5. Brand Positioning Matrix: Lonza
9.6. Brand Positioning Matrix: Merck
9.7. Brand Positioning Matrix: Sartorius
9.8. Brand Positioning Matrix: Thermo Fisher Scientific
10. PATENT ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Viral Vaccine Cell Culture Media: Patent Analysis
10.3.1. Analysis by Type of Patent
10.3.2. Analysis by Publication Year
10.3.3. Analysis by Granted Patents
10.3.4. Year-wise Trend of Filed Patent Applications
10.3.5. Analysis by Issuing Authority
10.3.6. Analysis by Patent Focus
10.3.7. Analysis by Patent Age
10.3.8. Analysis by CPC Symbols
10.3.9. Analysis by Type of Applicant
10.3.10. Leading Players: Analysis by Number of Patents
10.4. Viral Vaccine Cell Culture Media: Patent Benchmarking Analysis
10.4.1. Analysis by Patent Characteristics
10.4.2. Analysis by Geography
10.5. Viral Vaccine Cell Culture Media: Patent Valuation Analysis
11. DEMAND ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Global Demand for Viral Vaccine
11.3.1. Global Demand for Scale of Operation
11.3.1.1. Clinical Demand for Viral Vaccine
11.3.1.2. Commercial Demand for Viral Vaccine
11.4.1. Geographical Analysis of Demand
11.4.1.1. Overall Demand in North America for Viral Vaccine
11.4.1.2. Overall Demand in Europe for Viral Vaccine
11.4.1.3. Overall Demand in Asia-Pacific and Rest of the World for Viral Vaccine
12. MARKET FORECAST
12.1. Chapter Overview
12.2. Forecast Methodology and Key Assumptions
12.3. Global Viral Vaccine Cell Culture Media Market, 2022-2035
12.4. Viral Vaccine Cell Culture Media Market: Analysis by Type of Cell Culture, 2022-2035
12.4.1. Viral Vaccine Cell Culture Media Market for Adherent Cell Culture, 2022-2035
12.4.2. Viral Vaccine Cell Culture Media Market for Suspension Cell Culture, 2022-2035
12.5. Viral Vaccine Cell Culture Media Market: Analysis by Type of Cell Culture Media, 2022-2035
12.5.1. Viral Vaccine Cell Culture Media Market for Animal Component Free Media, 2022-2035
12.5.2. Viral Vaccine Cell Culture Media Market for Protein Free Media, 2022-2035
12.5.3. Viral Vaccine Cell Culture Media Market for Serum Free Media, 2022-2035
12.6. Viral Vaccine Cell Culture Media Market: Analysis by Scale of Operation, 2022-2035
12.6.1. Viral Vaccine Cell Culture Media Market for Clinical Operations, 2022-2035
12.6.2. Viral Vaccine Cell Culture Media Market for Commercial Operations, 2022-2035
12.7. Viral Vaccine Cell Culture Media Market: Analysis by Type of End-User, 2022-2035
12.7.1. Viral Vaccine Cell Culture Media Market for Industry Players, 2022-2035
12.7.2. Viral Vaccine Cell Culture Media Market for Non-Industry Players, 2022-2035
12.8. Viral Vaccine Cell Culture Media Market: Analysis by Geography, 2022-2035
12.8.1. Viral Vaccine Cell Culture Media Market in North America, 2022-2035
12.8.2. Viral Vaccine Cell Culture Media Market in Europe, 2022-2035
12.8.3. Viral Vaccine Cell Culture Media Market in Asia-Pacific, 2022-2035
12.8.4. Viral Vaccine Cell Culture Media Market in Rest of the World, 2022-2035
13. CONCLUSION
13.1. Chapter Overview
14. INTERVIEW TRANSCRIPT(S)
15. APPENDIX I: TABULATED DATA
16. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
2.1. Chapter Overview
3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Viral Vaccine
3.2.1. Vaccine Components
3.2.2. Historical Evolution
3.2.3. Viral Vaccine Development
3.3. Type of Viral Vaccine
3.3.1. Whole Virus
3.3.2. Protein Subunit
3.3.3. Nucleic Acid
3.3.4 Viral Vector
3.4. Type of Cell Culture
3.5. Type of Cell Culture Media
3.6. Advantages of Cell Culture Media
3.7. Limitations Associated with Cell Culture Media
3.8. Conclusion
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Viral Vaccine Cell Culture Media: Overall Market Landscape
4.2.1. Analysis by Type of Vaccine
4.2.2. Analysis by Type of Cell Culture
4.2.3. Analysis by Type of Cell Culture Media
4.2.4. Analysis by Type of Cell Culture and Media
4.2.5. Analysis by Type of Cell Line
4.2.6. Analysis by Type of Cell Culture Media and Type of Cell Line
4.2.7. Analysis by Media Formulation
4.2.8. Analysis by Application Area
4.3. Viral Vaccine Cell Culture Media Developers: Market Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Analysis by Number of Products
5. COMPANY PROFILES
5.1. Chapter Overview
5.2. Players based in North America
5.2.1. Creative Biolabs
5.2.1.1. Company Overview
5.2.1.2. Financial Information
5.2.1.3. Product Portfolio
5.2.1.4. Future Outlook
5.2.2. Jianshun Biosciences
5.2.2.1. Company Overview
5.2.2.2. Financial Information
5.2.2.3. Product Portfolio
5.2.2.4. Future Outlook
5.2.3. Thermo Fisher Scientific
5.2.3.1. Company Overview
5.2.3.2. Financial Information
5.2.3.3. Product Portfolio
5.2.3.4. Future Outlook
5.3. Players based in Europe
5.3.1. Merck
5.3.1.1. Company Overview
5.3.1.2. Financial Information
5.3.1.3. Product Portfolio
5.3.1.4. Future Outlook
5.3.2. Sartorius
5.3.2.1. Company Overview
5.3.2.2. Financial Information
5.3.2.3. Product Portfolio
5.3.2.4. Future Outlook
5.3.3. Xell
5.3.3.1. Company Overview
5.3.3.2. Financial Information
5.3.3.3. Product Portfolio
5.3.3.4. Future Outlook
5.4. Players based in Asia-Pacific
5.4.1. ATZ labs
5.4.1.1. Company Overview
5.4.1.2. Financial Information
5.4.1.3. Product Portfolio
5.4.1.4. Future Outlook
5.4.2. OPM Biosciences
5.4.2.1. Company Overview
5.4.2.2. Financial Information
5.4.2.3. Product Portfolio
5.4.2.4. Future Outlook
6. RECENT DEVELOPMENTS AND INITIATIVES
6.1. Chapter Overview
6.2. Partnership Models
6.3. Viral Vaccine Cell Culture Media: Recent Partnerships and Collaborations
6.3.1. Analysis by Year of Partnership
6.3.2. Analysis by Type of Partnership
6.3.2.1. Analysis by Year and Type of Partnership
6.3.2.2. Analysis by Type of Partnership and Company Size
6.3.3. Most Active Players: Analysis by Number of Partnerships
6.3.4. Regional Analysis
6.3.4.1. Intercontinental and Intracontinental Agreements
6.3.5. Cumulative Year-wise Trend of Merger / Acquisition
6.3.6. Analysis by Type of Acquisition
6.3.7. Analysis by Key Value Drivers
6.3.8. Analysis by Year of Acquisition and Key Value Drivers
6.4. Viral Vaccine Cell Culture Media: Recent Expansions
7. LIKELY PARTNER ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Potential Strategic Partners for Viral Vaccine Cell Culture Media Developers
7.3.1. Likely Partner Opportunities in Preventive Vaccine Developers
7.3.2. Likely Partner Opportunities in Therapeutic Vaccine Developers
7.3.3. Likely Partner Opportunities in Vaccine Contract Manufacturers
8. PRODUCT COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Methodology
8.3. Assumptions / Key Parameters
8.4. Product Competitiveness: Adherent Cell Culture Media
8.5. Product Competitiveness: Suspension Cell Culture Media
9. BRAND POSITIONING
9.1. Chapter Overview
9.2. Key Parameters and Methodology
9.3. Brand Positioning Matrix: Cytiva
9.4. Brand Positioning Matrix: FUJIFILM Wako Chemicals
9.5. Brand Positioning Matrix: Lonza
9.6. Brand Positioning Matrix: Merck
9.7. Brand Positioning Matrix: Sartorius
9.8. Brand Positioning Matrix: Thermo Fisher Scientific
10. PATENT ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Viral Vaccine Cell Culture Media: Patent Analysis
10.3.1. Analysis by Type of Patent
10.3.2. Analysis by Publication Year
10.3.3. Analysis by Granted Patents
10.3.4. Year-wise Trend of Filed Patent Applications
10.3.5. Analysis by Issuing Authority
10.3.6. Analysis by Patent Focus
10.3.7. Analysis by Patent Age
10.3.8. Analysis by CPC Symbols
10.3.9. Analysis by Type of Applicant
10.3.10. Leading Players: Analysis by Number of Patents
10.4. Viral Vaccine Cell Culture Media: Patent Benchmarking Analysis
10.4.1. Analysis by Patent Characteristics
10.4.2. Analysis by Geography
10.5. Viral Vaccine Cell Culture Media: Patent Valuation Analysis
11. DEMAND ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Global Demand for Viral Vaccine
11.3.1. Global Demand for Scale of Operation
11.3.1.1. Clinical Demand for Viral Vaccine
11.3.1.2. Commercial Demand for Viral Vaccine
11.4.1. Geographical Analysis of Demand
11.4.1.1. Overall Demand in North America for Viral Vaccine
11.4.1.2. Overall Demand in Europe for Viral Vaccine
11.4.1.3. Overall Demand in Asia-Pacific and Rest of the World for Viral Vaccine
12. MARKET FORECAST
12.1. Chapter Overview
12.2. Forecast Methodology and Key Assumptions
12.3. Global Viral Vaccine Cell Culture Media Market, 2022-2035
12.4. Viral Vaccine Cell Culture Media Market: Analysis by Type of Cell Culture, 2022-2035
12.4.1. Viral Vaccine Cell Culture Media Market for Adherent Cell Culture, 2022-2035
12.4.2. Viral Vaccine Cell Culture Media Market for Suspension Cell Culture, 2022-2035
12.5. Viral Vaccine Cell Culture Media Market: Analysis by Type of Cell Culture Media, 2022-2035
12.5.1. Viral Vaccine Cell Culture Media Market for Animal Component Free Media, 2022-2035
12.5.2. Viral Vaccine Cell Culture Media Market for Protein Free Media, 2022-2035
12.5.3. Viral Vaccine Cell Culture Media Market for Serum Free Media, 2022-2035
12.6. Viral Vaccine Cell Culture Media Market: Analysis by Scale of Operation, 2022-2035
12.6.1. Viral Vaccine Cell Culture Media Market for Clinical Operations, 2022-2035
12.6.2. Viral Vaccine Cell Culture Media Market for Commercial Operations, 2022-2035
12.7. Viral Vaccine Cell Culture Media Market: Analysis by Type of End-User, 2022-2035
12.7.1. Viral Vaccine Cell Culture Media Market for Industry Players, 2022-2035
12.7.2. Viral Vaccine Cell Culture Media Market for Non-Industry Players, 2022-2035
12.8. Viral Vaccine Cell Culture Media Market: Analysis by Geography, 2022-2035
12.8.1. Viral Vaccine Cell Culture Media Market in North America, 2022-2035
12.8.2. Viral Vaccine Cell Culture Media Market in Europe, 2022-2035
12.8.3. Viral Vaccine Cell Culture Media Market in Asia-Pacific, 2022-2035
12.8.4. Viral Vaccine Cell Culture Media Market in Rest of the World, 2022-2035
13. CONCLUSION
13.1. Chapter Overview
14. INTERVIEW TRANSCRIPT(S)
15. APPENDIX I: TABULATED DATA
16. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
